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Transplantation Rénale, Hôpital Nord, CHU de Saint-Etienne, France, 21Service de Néphrologie, Hémodialyse,
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ABSTRACT
Background. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation is routinely used to
assess renal function but exhibits varying accuracy depending on patient characteristics and clinical presentation. The
overall aim of the present study was to assess if and to what extent glomerular filtration rate (GFR) estimation based on
creatinine can be improved.
Methods. In a cross-sectional analysis covering the years 2003–17, CKD-EPI was validated against measured GFR (mGFR;
using various tracer methods) in patients with high likelihood of chronic kidney disease (CKD; five CKD cohorts, n¼8365)
and in patients with low likelihood of CKD (six community cohorts, n¼6759). Comparisons were made with the Lund–
Malmö revised equation (LMR) and the Full Age Spectrum equation.
Results. 7In patients aged 18–39 years old, CKD-EPI overestimated GFR with 5.0–16 mL/min/1.73 m2 in median in both cohort
types at mGFR levels <120 mL/min/1.73 m2. LMR had greater accuracy than CKD-EPI in the CKD cohorts (P30, the percentage
of estimated GFR within 30% of mGFR, 83.5% versus 76.6%). CKD-EPI was generally the most accurate equation in the
community cohorts, but all three equations reached P30 above the Kidney Disease Outcomes Quality Initiative benchmark
of 90%.
Conclusions. None of the evaluated equations made optimal use of available data. Prospects for improved GFR estimation
procedures based on creatinine exist, particularly in young adults and in settings where patients with suspected or
manifest CKD are investigated.
Keywords: chronic kidney disease, creatinine, glomerular filtration rate, kidney function tests, renal failure
INTRODUCTION
In 2013, the Kidney Disease: Improving Global Outcomes work
group recommended clinical laboratories to report estimated
glomerular filtration rate (eGFR) in adults using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine
equation [1], unless an alternative equation improves accuracy
of glomerular filtration rate (GFR) estimates [2]. This recommen-
dation has made the use of CKD-EPI common practice in many
hospitals. However, there is evidence suggesting that GFR esti-
mations based on creatinine can be improved in patients with
known or suspected chronic kidney disease (CKD) [3–9].
Moreover, the CKD-EPI equation is not intended for the entire
life span, as the present formulation of the equation severely
overestimates GFR in children [10, 11]. This restricted scope of
the CKD-EPI equation also most likely explains its substantial
overestimation and low accuracy among young adults [6, 11,
12], and the implausible changes in eGFR when switching from
the recommended creatinine-based Chronic Kidney Disease in
Children equation (‘Schwartz bedside’) in paediatric care to
CKD-EPI in adults [13]. Thus, although GFR estimation based on
creatinine has a long history [14], it seems to still be an area
where improvements can be made. Guidance in future refine-
ment of GFR equations and estimation approaches are war-
ranted from more solid empirical evidence from external
validation studies.
It is essential to distinguish between ‘diagnostic correctness’
and ‘diagnostic predictiveness’ when investigating GFR estima-
tion accuracy [15]. Diagnostic correctness represents GFR esti-
mation accuracy stratified by measured GFR (clearance of
external tracers, mGFR) and is analogous to sensitivity and spe-
cificity of a binary test. For binary tests, there is a trade-off be-
tween sensitivity and specificity, which for GFR equations
corresponds to a trade-off between accuracy of eGFR among
patients with and without renal impairment [15, 16]. However,
when a diagnostic test is used in clinical practice typically, the
index test (eGFR) but not the reference method (mGFR) is avail-
able. Diagnostic predictiveness represents GFR estimation accu-
racy stratified by eGFR, analogous to presenting predictive
values of a binary test for use in the clinical situation [15].
Diagnostic predictiveness is dependent not only on sensitivity
(accuracy at low mGFR) and specificity (accuracy at normal
mGFR), but also on the clinical setting, e.g. primary versus spe-
cialized healthcare and the resulting distribution of patient
characteristics, symptomatology and severity of renal disease
[15, 17]. Most validation studies of GFR equations have focused
on diagnostic correctness [15, 18] and have often pooled data
from different populations. However, overall validation in
pooled data adds little insight into diagnostic predictiveness, as
the pooling makes the study population and underlying clinical
setting poorly defined [19]. Additionally, few studies have
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studied diagnostic accuracy at two or more dimensions simulta-
neously, e.g. mGFR and age [9, 13, 20].
The overall aim of the present cross-sectional multicentre
study was to assess if and to what extent diagnostic predictive-
ness of GFR estimation based on creatinine can be improved in
two distinct clinical settings: (i) patients with high prior likeli-
hood of CKD and (ii) patients with low prior likelihood of CKD.
We compared CKD-EPI with one GFR equation developed specif-
ically for use in patients with suspected or confirmed CKD [the
Lund–Malmö revised equation (LMR)] [21] and one primarily
intended for use in patients with no prior suspicion of CKD [the
Full Age Spectrum (FAS) equation] [7, 22].
MATERIALS AND METHODS
Patient data
The European Kidney Function Consortium (EKFC), a new work-
ing group under the umbrella of the ERA-EDTA, has taken the
initiative to pool and structure data on mGFR, plasma/serum
creatinine, age, sex, height and weight of Europeans and non-
black North Americans aged 18 years. Data were obtained
from 11 cohorts (Supplementary data, Table S1) used in ongoing
or published cross-sectional and longitudinal studies in France
[7, 8, 23, 24], the UK [7–9, 25], Germany [7–9, 26], Norway [7, 8,
27], Sweden [4, 6, 9, 28, 29] and the USA [7, 8, 30, 31]. We classi-
fied the individual cohorts according to the clinical setting: (i)
patients with high prior likelihood of CKD (labelled ‘CKD
cohorts’; n¼ 5) and (ii) patients with low prior likelihood of CKD
(labelled ‘community cohorts’; n¼ 6). Common causes for refer-
ral in the CKD cohorts were manifest or suspected diabetic ne-
phropathy, interstitial nephritis, glomerulonephritis, nephrotic
syndrome, haematuria, proteinuria, reflux nephropathy, mye-
loma, vasculitis, consideration of initiation of haemodialysis,
control after organ transplantation and to dose drugs cleared by
the kidneys. The community cohorts included studies of gen-
eral populations, healthy older people and potential kidney
donors.
Patient data were pooled in an anonymous database for the
present study at Lund University, Sweden. All procedures in-
volving subjects and data followed the ethical principles for
medical research involving human subjects established in the
World Medical Association Declaration of Helsinki. For this type
of retrospective study, all extracted data were fully anonymous
without any personal information, therefore informed consent
was not required according to the Regional Ethical Board ap-
proval in Lund, Sweden, which approved the study (Dnr 2018/
220). The present study was limited to the first measurement of
GFR in each patient, resulting in 8365 patients in the CKD
cohorts (median age 60 years, 45% females, median mGFR
58 mL/min/1.73 m2) and 6759 patients in the community cohorts
(median age 59 years, 55% females, median mGFR 88 mL/min/
1.73 m2; Table 1).
Laboratory methods
Details of laboratory methods used are summarized in
Supplementary data, Table S2. Clearance methods for determi-
nation of GFR (mGFR) included renal clearance of inulin, chro-
mium-51 labelled ethylene-diamine-tetra-acetic-acid (51Cr-
EDTA) and iothalamate, and plasma clearance of iohexol, all
considered acceptable as reference tests [32]. Samples of creati-
nine were obtained on the day of GFR measurement in all
cohorts but Stockholm, where samples within 48 h of mGFR
were accepted. All centres used creatinine assays traceable to
isotope dilution mass spectrometry (IDMS) and standardized
against primary reference material (National Institute of
Standards and Technology Standard Reference Material 967),
except for Kent, where it was measured directly with IDMS [25].
GFR equations
The CKD-EPI, FAS and LMR creatinine equations are presented
in the Supplementary material. None of the included cohorts
has been used for the development of any of the equations.
Statistical evaluation
Statistical evaluations were conducted using SPSS Statistics
(version 25; IBM Corp.), STATA (version 14; StataCorp) and R
(version 3.5.2), focussing on bias, precision and accuracy [33].
‘Bias’ was defined as the median of the individual differences
between eGFR and mGFR in mL/min/1.73 m2. ‘Precision’ was
assessed as the interquartile range (IQR) of the differences
eGFR – mGFR. ‘Accuracy’ was assessed from the absolute error
jeGFR – mGFRj/mGFR and summarized as the median absolute
percentage difference (absolute accuracy) and as the percentage
of estimates within 610% and 630% of mGFR (P10 and P30). The
complementary value 1 – P30 reflects the proportion of ‘large’ es-
timation errors [34]. The Kidney Disease Outcome Quality
Initiative (K/DOQI) 2002 benchmark is to reach P30 accuracy of
90% [35, 36]. Equation performance was evaluated against this
benchmark. We also assessed equation performance using pair-
wise comparisons with CKD-EPI equation as benchmark.
Non-parametric and asymptotic 95% confidence intervals
(CIs) were calculated as measures of the statistical uncertainty
in medians and proportions (P10/P30) of the overall results, re-
spectively. CIs for IQR were estimated from the 2.5 to 97.5 per-
centiles of a simulated distribution obtained using a bootstrap
method with 10 000 replications [37].
Diagnostic correctness—stratification by mGFR. Evaluation of
diagnostic correctness implies analysis of equation








Age, years 60 (18–84) 59 (30–84)
Females, n (%) 3758 (45) 3722 (55)
Weight, kg 75 (45–118) 75 (50–112)
Height, cm 170 (151–188) 168 (152–186)
Body surface area, m2 1.86 (1.42–2.34) 1.85 (1.49–2.30)
BMI, kg/m2 25 (17–40) 26 (19–38)
Plasma/serum creatinine, lmol/L 102 (46–377) 70 (47–122)
mGFR, mL/min/1.73 m2 58 (12–123) 88 (41–128)
mGFR, n (%), mL/min/1.73 m2
<30 1752 (21) 30 (0.4)
30–44 1310 (16) 206 (3.0)
45–59 1279 (15) 452 (6.7)
60–89 2306 (28) 2891 (43)
90–119 1426 (17) 2824 (42)
120 292 (3.5) 356 (5.3)
Descriptive measures given as median values (2.5 and 97.5 percentiles) if not
stated otherwise
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performance (bias, precision and accuracy) stratified by mGFR,
analogous to reporting sensitivity and specificity of a binary test
[15]. We collapsed the two cohort types to improve statistical
precision and presented diagnostic correctness in a simulta-
neous stratification by mGFR (<30, 30–59, 60–89, 90–119 and
120 mL/min/1.73 m2) and age (18–39, 40–59, 60–69 and
70 years). We also added sex (female and male) as a third di-
mension to this stratification.
Diagnostic predictiveness—stratification by estimated GFR.
Evaluation of diagnostic predictiveness implies analysis of
equation performance (bias, precision and accuracy) stratified
by estimated GFR, analogous to presenting predictive values of
a binary test for use in the clinical situation [15]. ‘Accuracy dia-
grams’ were constructed using quantile regression with frac-
tional polynomials (linear, logarithm and square) as input to
illustrate how the estimation errors varied across eGFR for each
equation in the two population types [15, 16]. In the diagrams,
we expressed estimation errors in mL/min/1.73 m2 using the
quantiles (percentiles) Q10, Q50 (median bias) and Q90, where the
accuracy interval (AI, Q10–Q90), reflects the largest estimation er-
ror with 80% certainty. The presentation was limited to the
range between 1% and 99% percentile of the estimated GFR val-
ues for each equation to limit the statistical uncertainty in the
tails of the quantile curves. The constancy of bias stratified by
eGFR in the accuracy diagrams is an indicator of how similarly
an equation behaves in the validation compared with the origi-
nal development cohort [16, 18].
Performance in a given eGFR range of each equation cannot
be directly compared because it is unlikely that all evaluated
equations produce GFR estimates within that range for the
same set of patients [15]. Results in tables were therefore strati-
fied by eGFR values calculated from the CKD-EPI equation
(eGFRCKD-EPI: <30, 30–59, 60–89, 90–119 and 120 mL/min/
1.73 m2) to permit direct comparison of diagnostic predictive-
ness between the equations in the same patients. Since diag-
nostic predictiveness is dependent on pretest likelihood of
disease [17], performance was evaluated for each population
type (CKD and community) separately. Quantile regression was
used in multivariable models to investigate how the median
bias was dependent not only on eGFRCKD-EPI in the intervals de-
fined above, but also on age, sex and body mass index (BMI;
<18.5, 18.5–24.9, 25.0–29.9 and 30.0 kg/m2).
RESULTS
Overall results by cohort type
All three equations showed no major bias overall but substan-
tial imprecision in both the CKD and community cohorts. In the
CKD cohorts, none of them reached the K/DOQI 2002 benchmark
of a P30 accuracy 90%, while they all reached this benchmark
in the community cohorts (Table 2). LMR had better bias, higher
precision and greater accuracy than both CKD-EPI and FAS in
the CKD cohorts. The P30 difference was seven percentage
points (P30¼ 83.5% for LMR versus 76.6% for CKD-EPI and 76.5%
Table 2. Bias, precision, accuracy (95% CIs) of CKD-EPI, FAS and LMR in the CKD and community cohorts
Equations Bias Precision Absolute error (%) P10 (%) P30 (%)
(mL/min/1.73 m2) (mL/min/1.73 m2)
CKD cohorts (n¼ 8365)
CKD-EPI 3.8 (3.5–4.1) 16.6 (16.1–17.0) 16.0 (15.6–16.4) 33.4 (32.3–34.4) 76.6 (75.7–77.5)
FAS 3.3 (3.0–3.6) 15.5 (15.0–16.0) 15.3 (14.9–15.7) 34.3 (33.3–35.3) 76.5 (75.6–77.4)
LMR 1.4 (1.7, 1.1) 14.4 (14.0–14.8) 14.1 (13.8–14.5) 35.9 (34.9–37.0) 83.5 (82.7–84.3)
Community cohorts (n¼ 6759)
CKD-EPI 2.1 (1.8–2.6) 17.2 (16.7–17.7) 10.4 (10.1–10.7) 48.6 (47.4–49.8) 91.0 (90.4–91.7)
FAS 1.4 (1.8, 1.0) 17.8 (17.3–18.3) 10.8 (10.5–11.0) 46.9 (45.7–48.0) 91.9 (91.3–92.6)
LMR 6.7 (7.0, 6.4) 16.7 (16.2–17.1) 11.5 (11.2–11.8) 43.7 (42.5–44.9) 92.8 (92.1–93.4)
Median bias (eGFR mGFR) and precision (IQR) expressed in mL/min/1.73 m2, absolute error expressed as median absolute percentage error jeGFRmGFRj/mGFR and
P10 and P30 accuracy (percentage of GFR estimates within 10% and 30% of mGFR).
FIGURE 1: The proportion of patients with sufficiently accurate estimated GFR (y-axis) at different requirements on highest percentage absolute error (x-axis), that is,
from 10% to 50% (P10–P50) in relation to mGFR. (A) CKD cohorts and (B) community-based cohorts. In the example indicated by the arrows, P20 ranged between about
60% (CKD-EPI and FAS) and 66% (LMR) in (A) and was about 78% for all three equations in (B).






/ckj/article/13/4/674/5857035 by guest on 04 February 2021
for FAS), which corresponds to seven fewer estimation errors
exceeding 30% per 100 tested CKD patients if LMR is used.
Differences between the equations in the P10–P50 accuracy range
were larger in the CKD than in the community cohorts
(Figure 1). CKD-EPI was generally the most accurate equation in
the community cohorts, as reflected by lower absolute percent-
age error and higher P10 than the two other equations, but the
difference versus FAS was smaller than versus LMR (Table 2).
Statistical evaluations of the pairwise comparisons in perfor-
mance with CKD-EPI as benchmark are presented stratified by
cohort type in Supplementary data, Table S3. All comparisons
had narrow CIs as a result of the large cohort sizes. Results for
the 11 individual cohorts are presented in Supplementary data,
Table S4.
Diagnostic correctness—results stratified by mGFR, age
and sex
LMR was generally the least biased equation at all ages in
patients with known GFR (mGFR) <90 mL/min/1.73 m2 (Table 3).
It was generally also more precise than CKD-EPI and generally
more accurate than both CKD-EPI and FAS at all mGFR levels
<90 mL/min/1.73 m2 (Supplementary data, Table S5A–C). CKD-
EPI and FAS showed marked overestimations at younger ages at
all mGFR levels <90 or 120 mL/min/1.73 m2, respectively
(Table 3). As an example, CKD-EPI overestimated GFR by 13 mL/
min/1.73 m2 (95% CI 11.5–15.5 mL/min/1.73 m2) on average in
individuals <40 years of age with mGFR 30–59 mL/min/1.73 m2.
LMR exhibited noticeable underestimation in patients with
mGFR >90 mL/min/1.73 m2 (Table 3). CKD-EPI and FAS also
yielded underestimations in patients with high mGFR but mostly
to a lesser degree than LMR. LMR and CKD-EPI were both more
precise than FAS at mGFR >90 mL/min/1.73 m2 (Supplementary
data, Table S5A), but CKD-EPI was more accurate due to its lower
bias (Supplementary data, Tables S5B and S5C). None of the three
equations showed any consistent differences in bias among
females and males (Supplementary data, Table S6).
Diagnostic predictiveness—results stratified by
estimated GFR and cohort type
The accuracy diagrams further illustrate the substantial impre-
cision across eGFR for all three equations and in both two popu-
lation types (Figure 2). Low and constant bias were seen both for
LMR in the CKD cohorts and for CKD-EPI in the community
cohorts at eGFR <120 mL/min/1.73 m2.
In the CKD cohorts, LMR had lower bias and higher accuracy
than CKD-EPI in patients with eGFR >60 mL/min/1.73 m2 accord-
ing to the CKD-EPI equation (eGFRCKD-EPI; Table 4). Estimates of
the CKD-EPI equation >120 mL/min/1.73 m2 occurred among 9%
of all patients in the CKD cohorts, most of them young (median
age 21 years). The overestimation exceeded 20 mL/min/1.73 m2
on average for these patients when CKD-EPI or FAS was used,
whereas the estimates from LMR were virtually unbiased for the
same patients. In particular, FAS exhibited imprecision at
eGFRCKD-EPI >120 mL/min/1.73 m
2 (Table 4).
In the community cohorts, changing equation from CKD-EPI
to either FAS or LMR would not consistently improve accuracy
in patients with eGFRCKD-EPI <120 mL/min/1.73 m
2 (98% of all
patients; Table 5). FAS exhibited increasing overestimations at
high eGFRCKD-EPI in the community cohorts. The underestima-
tion of LMR varied between 4 and 7 mL/min/1.73 m2 across
all levels of eGFRCKD-EPI. None of the three equations was
consistently more precise than the others across all levels of
eGFRCKD-EPI.
Multivariable quantile regression based on eGFRCKD-EPI, age,
sex and BMI confirmed the substantial overestimations for
CKD-EPI and FAS at high levels of eGFRCKD-EPI in the CKD cohorts
(Table 6). Additionally, overestimation due to underweight was
noted for all three equations and with similar magnitude.
Table 3. Diagnostic correctness (bias stratified by mGFR) in the two cohort types combined (CKD and community; n 5 15 124)
Age intervals (years)
mGFR 18–39 40–59 60–69 70
<30, number 101 270 338 1073
CKD-EPI 5.0 (3.6–7.0) 1.4 (0.7–2.8) 2.9 (2.1–3.9) 2.0 (1.5–2.5)
FAS 9.7 (7.8–12.7) 6.6 (5.5–7.6) 5.6 (4.8–6.4) 2.9 (2.5–3.3)
LMR 2.8 (1.6–3.8) 1.2 (0.4–1.9) 1.8 (1.1–2.5) 0.2 (20.2, 0.7)
30–59, number 381 656 767 1443
CKD-EPI 13.4 (11.5–15.5) 3.7 (2.6–5.0) 3.4 (2.0–4.4) 4.0 (3.4–4.6)
FAS 14.5 (13.0–16.4) 7.1 (6.0–8.3) 2.7 (1.8–3.8) 20.2 (20.8, 0.2)
LMR 6.3 (4.1–8.6) 1.3 (0.3–2.6) 0.6 (20.9, 1.9) 0.3 (0.8, 0.5)
60–89, number 736 1772 1556 1133
CKD-EPI 15.6 (13.6–17.3) 8.0 (7.3–8.9) 7.0 (6.2–7.6) 5.9 (5.1–5.6)
FAS 10.9 (9.5–12.2) 4.4 (3.8–5.1) 20.4 (21.0, 0.3) 24.5 (25.5, 23.8)
LMR 2.6 (1.4–3.8) 20.1 (20.7, 0.5) 22.2 (22.7, 21.6) 24.4 (25.2, 23.9)
90–119, number 1278 2088 798a 147a
CKD-EPI 10.4 (9.2–11.5) 21.9 (22.5, 21.4) 25.3 (26.1, 24.5) 29.5 (212.2, 27.0)
FAS 4.4 (3.4–6.0) 2.8 (3.4, 2.2) 9.5 (10.8, 8.5) 14.2 (16.8, 12.7)
LMR 9.0 (9.8, 8.3) 12.0 (12.5, 11.5) 15.1 (16.0, 14.1) 20.0 (22.3, 18.1)
120, number 338 249 –a –a
CKD-EPI 25.2 (27.3, 22.8) 23.9 (26.4, 21.2)
FAS 5.8 (9.3, 3.3) 217.9 (221.4, 215.1)
LMR 25.7 (27.0, 24.2) 232.4 (235.7, 231.0)
Median bias (eGFR – mGFR in mL/min/1.73 m2; 95% CIs) of CKD-EPI, FAS and LMR stratified by mGFR and age (years). The lowest bias is marked with bold and italic in
each stratum.
amGFR intervals 120 were collapsed with 90–119 due to small numbers (n<100).
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Age and sex did not have strong independent effects on bias for
any of the three equations in the CKD cohorts. Bias varied more
noticeably with eGFRCKD-EPI for CKD-EPI and FAS than for LMR
also in the multivariable quantile regression models for the
community cohorts (Table 6). In addition, bias varied according
to age for CKD-EPI and LMR. Being male increased the underes-
timation of the LMR equation. BMI at any level was not related
to bias for any of the three equations in the community cohorts.
DISCUSSION
The salient finding of our comprehensive validation study is
that prospects for improved GFR estimation based on creatinine
still exist. The widely used CKD-EPI equation was generally suf-
ficiently accurate with P30 exceeding 90% only in patients with
low likelihood of CKD, but it was neither the most accurate
equation in patients with known or suspected renal impairment
nor the most accurate in young adults irrespective of their renal
status. The FAS equation shared similar weaknesses as CKD-EPI
when applied in the CKD cohorts and in young adults. LMR, on
the other hand, was the most accurate equation among patients
with high likelihood of CKD but did not perform as well in the
community cohorts.
The explanation for the superior accuracy of LMR in patients
with known or suspected renal impairment may be that the
equation was formulated with the explicit goal to improve sen-
sitivity (estimations in CKD patients) [21], whereas the goal of
developing CKD-EPI was to improve specificity (estimations in
patients with normal mGFR) [1]. The development of FAS
was established from a mathematical construction based on
FIGURE 2: Estimation errors (eGFR – mGFR in mL/min/1.73 m2 on the Y-axis) at different levels of eGFR on the X-axis (diagnostic predictiveness) in the CKD cohorts for
(A) CKD-EPI, (B) FAS and (C) LMR and in the community cohorts for (D) CKD-EPI, (E) FAS and (F) LMR. The quantile regression curves for the estimation errors reflect
bias (Q50; solid line) and estimation error with 80% certainty (accuracy interval Q10–Q90; dashed lines). Note that the curves are of different length as they are truncated
at the 1 and 99% percentile of the estimated GFR values for each equation.
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age-average GFR and population-normalized serum creatinine
valid for a healthy population [7, 22], which may explain its
poor performance in patients with severe CKD.
The noticeable differences in performance depending on co-
hort type suggest that incorporation of prior information about
the patient’s disease history (e.g. pre-test probability of CKD)
could improve estimation accuracy. More complex GFR estima-
tion procedures, either rule-based choice of equation depending
on clinical setting or machine learning algorithms [38], would
open up the possibility of fine-grained estimations depending on,
for example, age or pre-test probability of CKD. Such estimation
procedures should ideally be applicable for the full age span of
children, adults and older people, and use of cystatin C when
available, and could also incorporate other patient characteristics
such as height and weight to avoid overestimation of GFR in un-
derweight patients. However, complex algorithms are often less
transparent than explicitly formulated estimating equations,
which means that a thorough assessment of algorithm fairness
and accountability is warranted before implementation [39].
A major strength of the present study was the large sample
size, which allowed for evaluation of diagnostic accuracy with
sufficient statistical precision in three dimensions simulta-
neously (mGFR, age and sex). Another strength was the consis-
tent stratification on cohort type in the evaluation of diagnostic
predictiveness, as clinical presentation and related prevalence
of CKD is fundamental for the interpretation of eGFR. This strat-
ification, for example, highlighted how the expected error in
eGFR as well as the influence of low BMI may differ importantly
depending on clinical setting. Yet, another strength was that
measurement of plasma/serum creatinine was based on enzy-
matic assays or directly measured with IDMS in all but two
cohorts that only partly used Jaffe. A major limitation was that
available data did not allow for separate validation in additional
subgroups such as patients with diabetes, malignant disease or
with organ transplantation, or other ethnicities than Europeans
and non-black North Americans. The initial CKD-EPI study sug-
gested that eGFR based on creatinine must be multiplied by a
correction factor (1.159) to yield valid results for African
Table 4. Diagnostic predictiveness (bias, precision and accuracy stratified by eGFR) in CKD cohorts
eGFRCKD-EPI Number Age (years) BMI (kg/m
2) Equation Bias (mL/min/1.73 m2) Precision (mL/min/1.73 m2) Absolute error (%) P30 (%)
<30 1504 72 27 CKD-EPI 20.3 (20.7, 0.0) 6.8 (6.4–7.2) 18.1 (16.8–18.9) 74.5 (72.3–76.7)
FAS 2.0 (1.6–2.2) 7.0 (6.7–7.4) 19.6 (18.2–20.8) 68.4 (66.1–70.8)
LMR 1.1 (1.4, 0.8) 6.7 (6.4, 7.2) 17.8 (17.0–18.6) 77.1 (75.0–79.3)
30–59 2419 65 27 CKD-EPI 1.6 (1.2–2.1) 12.5 (11.9–13.3) 15.3 (14.7–16.0) 78.6 (77.0–80.3)
FAS 1.9 (1.5–2.4) 13.5 (13.0–14.2) 15.8 (15.2–16.6) 76.6 (74.9–78.3)
LMR 1.8 (2.4, 1.4) 12.6 (11.9–13.1) 15.7 (14.9–16.4) 81.1 (79.5–82.7)
60–89 2130 58 25 CKD-EPI 6.5 (5.6–7.2) 19.7 (18.9–20.8) 15.8 (14.8–16.6) 76.3 (74.5–78.1)
FAS 1.8 (1.0–2.7) 19.7 (18.7–20.7) 14.0 (13.3–14.5) 82.1 (80.5–83.7)
LMR 20.7 (21.4, 0.0) 18.8 (18.0–19.9) 13.8 (13.2–14.3) 84.0 (82.4–85.5)
90–119 1578 46 24 CKD-EPI 10.1 (9.2–11.2) 21.2 (20.2–22.4) 13.6 (12.7–14.6) 80.4 (78.5–82.4)
FAS 7.3 (6.4–8.0) 21.8 (20.5–23.2) 12.6 (12.1–13.4) 81.6 (79.6–83.5)
LMR 22.8 (23.7, 21.8) 20.8 (19.7–22.0) 11.7 (11.1–12.3) 90.1 (88.6–91.6)
120 734 21 21 CKD-EPI 22.5 (20.6–23.8) 24.3 (22.3–25.8) 21.1 (19.2–22.5) 67.0 (63.6–70.4)
FAS 20.4 (17.9–22.3) 33.7 (30.7–37.1) 19.6 (17.7–21.9) 65.8 (62.4–69.2)
LMR 20.6 (22.9, 1.1) 25.2 (22.9–27.4) 11.2 (10.6–12.4) 88.7 (86.4–91.0)
Estimation results for CKD-EPI, FAS and LMR (95% CI) stratified by eGFR (mL/min/1.73 m2) based on the CKD-EPI equation (eGFRCKD-EPI). The best result for each perfor-
mance marker is marked with bold and italic in each stratum. Number of patients, median age (years) and BMI (kg/m2) are given in each stratum Median bias (eGFR 
mGFR) and precision (IQR) expressed in mL/min/1.73 m2. Absolute error expressed as median absolute percentage error jeGFR mGFRj/mGFR, and P10 and P30 accuracy
(percentage of GFR estimates within 10% and 30% of mGFR).
Table 5. Diagnostic predictiveness (bias, precision and accuracy stratified by eGFR) in community cohorts
eGFRCKD-EPI Number Age (years) BMI (kg/m
2) Equations Bias (mL/min/1.73 m2) Precision (mL/min/1.73 m2) Absolute error (%) P30 (%)
<60a 473 78 27 CKD-EPI 20.2 (21.2, 0.6) 12.8 (12.2–14.5) 13.7 (12.2–15.5) 83.7 (80.4–87.1)
FAS 4.3 (5.0, 3.4) 12.2 (10.7–13.9) 13.9 (12.8–15.5) 85.4 (82.2–88.6)
LMR 4.5 (5.2, 3.3) 11.9 (10.9–13.8) 15.1 (13.8–16.1) 82.5 (79.0–85.9)
60–89 2479 63 27 CKD-EPI 1.0 (0.4–1.7) 18.2 (17.3–19.0) 11.6 (11.1–12.2) 85.7 (82.4–89.0)
FAS 5.8 (6.2, 5.2) 15.5 (14.8–16.3) 11.7 (11.2–12.2) 92.7 (91.6–93.7)
LMR 7.1 (7.6, 6.5) 16.3 (15.5–17.1) 12.4 (12.0–12.9) 91.4 (90.3–92.5)
90–119 3687 55 26 CKD-EPI 3.0 (2.6–3.6) 17.0 (16.4–17.7) 9.2 (8.9–9.7) 88.9 (87.6–90.1)
FAS 2.2 (1.7–2.7) 18.4 (17.7–19.2) 9.6 (9.2–10.0) 92.9 (92.1–93.7)
LMR 7.0 (7.6, 6.5) 17.2 (16.6–17.8) 10.7 (10.3–11.0) 94.8 (94.0–95.5)
120 120 29 23 CKD-EPI 12.9 (6.9–15.6) 18.7 (15.4–22.5) 12.8 (10.7–15.6) 92.5 (87.7–97.3)
FAS 19.3 (15.5–23.2) 26.8 (20.5–29.7) 16.3 (14.0–21.9) 73.3 (65.3–81.4)
LMR 24.5 (27.9, 21.8) 19.1 (16.0–23.9) 9.6 (8.6–10.6) 98.3 (94.1–99.8)
Estimation results for CKD-EPI, FAS and LMR (95% CI) stratified by eGFR (mL/min/1.73 m2) based on the CKD-EPI equation (eGFRCKD-EPI). The best result for each perfor-
mance marker is marked with bold and italic in each stratum. Number of patients, median age (years) and BMI (kg/m2) are given in each stratum Median bias (eGFR 
mGFR) and precision (IQR) expressed in mL/min/1.73 m2. Absolute error expressed as median absolute percentage error jeGFR mGFRj/mGFR, and P10 and P30 accuracy
(percentage of GFR estimates within 10% and 30% of mGFR).
amGFR intervals <44 were collapsed with 45–59 due to small numbers (<100).
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Americans [1]. It seems logical to use the same correction factor
for other creatinine-based equations such as LMR (or FAS) to ex-
tend their applicability to African Americans. However, we be-
lieve that differences in creatinine generation should be
corrected at the creatinine level rather than at the GFR level to
avoid misleading interpretations that GFR differs between eth-
nicities. This may be achieved using the approach implemented
in the FAS equations [7, 40].
A potential limitation of the generalizability of the results is
that the Swedish data constituted two-thirds of patients in the
CKD cohorts. However, none of these cohorts has been used for
the development of LMR. The results of the Swedish cohorts
were consistent with those from another European centre, Lyon
(France), insofar as LMR performed better than CKD-EPI, while
the latter was more accurate in the North American Chronic
Renal Insufficiency Cohort Study (CRIC) cohort (Supplementary
data, Table S3). One possible explanation for these divergent
results may be differences in creatinine calibration. The CRIC
study used Siemens creatinine enzymatic assay recalculated to
the Roche Creatinine Plus assay, while the European cohorts all
used enzymatic assays traceable to primary reference materials
with values assigned by IDMS. Indirect creatinine calibration
was also used in the development and initial validation of the
CKD-EPI equation [1, 41], which may explain why this equation
performs less well in CKD cohorts where creatinine assays di-
rectly traceable to IDMS are used [42]. Another explanation for
diverging results across studies may be the use of different
methods when measuring GFR. However, apart from renal
clearance of inulin, considered the ‘gold standard’ for measur-
ing GFR, renal clearance of iothalamate and 51Cr-EDTA as well
as plasma clearance of iohexol have all been considered suffi-
ciently accurate methods to measure GFR [32]. In addition, the
single plasma sample method is highly concordant with a mul-
tiple sample strategy [43–45] providing that sampling time is
adjusted according to estimated renal function [46] as used in
the present cohorts.
In conclusion, the present study provides evidence that the
widespread CKD-EPI equation is generally sufficiently accurate
according to K/DOQI benchmark only in patients with low likeli-
hood of CKD. Accuracy of GFR estimation based on creatinine
can be improved in patients with known or suspected renal im-
pairment and in young adults. Caution is necessary when using
any of the three evaluated equations in clinical practice, as all
exhibited considerable imprecision. Incorporation of the pre-
test probability of CKD in the GFR estimation procedure can be
an important step towards improved accuracy of eGFR across
the full spectrum of age and renal function.
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Table 6. Diagnostic predictiveness (bias stratified for eGFR) in CKD and community cohorts
CKD cohorts Community cohorts
CKD-EPI FAS LMR CKD-EPI FAS LMR
Constanta 1.9 (0.6 – 3.2) 5.8 (4.6 – 7.1) 2.3 (3.5, 1.1) 10.4 (12.5, 8.3) 7.7 (9.9, 5.4) 16.7 (18.8, 14.7)
eGFRCKD-EPI
<30 Reference Reference Reference b b b
30 – 59 2.0 (1.0 – 3.0) 0.8 (1.8, 0.2) 0.8 (1.7, 0.2) Reference (<60) Reference (<60) Reference (<60)
60 – 89 6.7 (5.6 – 7.7) 1.3 (2.4, 0.3) 0.2 (0.8, 1.3) 6.1 (4.6 – 7.7) 0.7 (0.9, 2.4) 0.7 (0.8, 2.2)
90 – 119 10.1 (8.9 – 11.3) 3.2 (2.0 – 4.4) 1.4 (2.6, 0.3) 11.8 (10.1 – 13.4) 9.9 (8.1 – 11.7) 3.6 (2.0 – 5.2)
120 19.5 (17.9 – 21.1) 14.4 (12.8 – 16.0) 0.2 (1.3, 1.8) 22.4 (19.2 – 25.7) 26.3 (22.8 – 29.8) 10.1 (6.9 – 13.3)
Age
<40 Reference Reference Reference Reference Reference Reference
40 – 59 2.8 (3.8, 1.7) 0.2 (0.9, 1.2) 1.9 (0.9 – 2.9) 0.7 (2.0, 0.7) 0.4 (1.8, 1.0) 3.4 (2.1 – 4.7)
60 – 69 1.1 (2.2, 0.1) 1.9 (3.1, 0.8) 2.6 (1.6 – 3.7) 2.5 (1.0 – 3.9) 1.1 (2.7, 0.4) 5.7 (4.3 – 7.2)
70 0.1 (1.0, 1.2) 3.0 (4.0, 1.9) 2.6 (1.5 – 3.6) 10.0 (8.3 – 11.7) 3.3 (1.5 – 5.1) 11.0 (9.4 – 12.7)
Female 0.3 (1.0, 0.3) 1.3 (1.9, 0.6) 0.2 (0.4, 0.8) 2.6 (1.9 – 3.3) 1.0 (0.3 – 1.8) 4.2 (3.5 – 4.8)
BMI
<18.5 6.9 (5.4 – 8.4) 6.8 (5.3 – 8.3) 6.8 (5.4 – 8.2) 1.6 (3.6, 0.3) 0.9 (3.0, 1.2) 1.5 (3.4, 0.4)
18.5 – 24.9 Reference Reference Reference Reference Reference Reference
25.0 – 29.9 2.2 (3.0, 1.4) 1.9 (2.7, 1.1) 1.9 (2.7, 1.2) 0.0 (0.9, 0.8) 0.2 (1.1, 0.7) 0.0 (0.8, 0.8)
30.0 2.5 (3.4, 1.6) 2.0 (2.9, 1.1) 2.1 (2.9, 1.2) 0.1 (1.0, 0.9) 0.1 (1.1, 0.9) 0.2 (0.8, 1.1)
Multivariable quantile regression estimates of median bias (mL/min/1.73 m2; 95% CI) by cohort type and subgroups of eGFR (mL/min/1.73 m2) according to the CKD-EPI
equation (eGFRCKD-EPI), age (years), sex and BMI (kg/m
2).
The following example illustrates how to interpret the table by using CKD-EPI in the CKD cohort: a female (bias 1.9  0.3) aged 45 (bias 2.8) with a BMI of 17 (bias 6.9)
and an eGFR of 125 (bias 19.5) results in an estimated eGFR with a bias of 1.9 – 0.3 – 2.8 þ 6.9 þ 19.5¼25.2 mL/min/1.73 m2.
aThe constant reflects the estimated bias for an individual that belong to the reference group in all four dimensions (eGFR, age, sex and BMI).
bmGFR intervals <30 were collapsed with 30 – 59 due to small numbers.
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